Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Abbvie Inc (ABBV)
Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 241,478,368
  • Shares Outstanding, K 1,764,290
  • Annual Sales, $ 58,054 M
  • Annual Income, $ 11,836 M
  • 60-Month Beta 0.58
  • Price/Sales 4.06
  • Price/Cash Flow 7.38
  • Price/Book 18.30
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 18.84% ( -1.92%)
  • Historical Volatility 30.40%
  • IV Percentile 7%
  • IV Rank 10.50%
  • IV High 35.40% on 09/30/22
  • IV Low 16.89% on 05/01/23
  • Put/Call Vol Ratio 1.22
  • Today's Volume 38,509
  • Volume Avg (30-Day) 42,596
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 448,204
  • Open Int (30-Day) 440,299

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 2.93
  • Number of Estimates 6
  • High Estimate 2.99
  • Low Estimate 2.90
  • Prior Year 3.51
  • Growth Rate Est. (year over year) -16.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
131.10 +4.40%
on 06/01/23
151.51 -9.66%
on 05/03/23
-14.75 (-9.73%)
since 05/02/23
3-Month
131.10 +4.40%
on 06/01/23
166.20 -17.65%
on 04/25/23
-17.51 (-11.34%)
since 03/02/23
52-Week
131.10 +4.40%
on 06/01/23
168.11 -18.58%
on 01/06/23
-9.88 (-6.73%)
since 06/02/22

Most Recent Stories

More News
7 Best Dividend Stocks to Buy Now in June 2023

These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio.

TSCO : 211.19 (+2.36%)
BAC : 28.71 (+3.35%)
DE : 371.07 (+5.25%)
ABBV : 136.87 (+2.57%)
VICI : 31.61 (+2.17%)
SCHD : 71.24 (+1.96%)
NKE : 107.78 (+4.00%)
QCOM : 115.62 (-0.18%)
Is SNDL Inc. (SNDL) Overbought?

Canadian cannabis company SNDL Inc. (SNDL) enjoys major investor attention and belongs to the Robinhood top 100 stocks list. However, should investors consider buying this stock now? Read more… ...

ABBV : 136.87 (+2.57%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
SNDL : 1.4800 (+2.07%)
Why AbbVie and Amgen Are Moving Lower Today

An ultra-low-priced biosimilar may negatively impact both biotechs.

ABBV : 136.87 (+2.57%)
AMGN : 218.07 (+1.77%)
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary...

ABBV : 136.87 (+2.57%)
AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy...

ABBV : 136.87 (+2.57%)
CPRX : 11.55 (-0.77%)
Should You Add Shares of Tilray Brands (TLRY) to Your Portfolio?

Canadian cannabis leader Tilray Brands (TLRY) is bolstering its portfolio through expansions and partnerships. However, the company’s recent $150 million offering of senior notes put pressure on its...

ABBV : 136.87 (+2.57%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
TLRY : 1.7200 (+1.18%)
Is Canopy Growth (CGC) a Buy Under $2?

Canadian cannabis producer Canopy Growth (CGC) is making significant changes to its business model in an effort to turn profitable. However, given the regulatory challenges, will the company get success...

ABBV : 136.87 (+2.57%)
ALPMY : 16.0600 (-0.43%)
CGC : 0.8251 (-1.17%)
NVO : 157.14 (-0.53%)
2 Dividend Kings on Sale That Are Yielding More Than 4%

Before you rush out to buy these stocks, you should consider the risks that come with them.

ABBV : 136.87 (+2.57%)
MMM : 102.53 (+8.75%)
2 Top Dividend Kings to Buy for the Long Haul

Dividend stocks are an easy way to earn passive income.

ABBV : 136.87 (+2.57%)
KO : 61.16 (+1.93%)
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials –...

ABBV : 136.87 (+2.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 141.53
2nd Resistance Point 139.25
1st Resistance Point 138.06
Last Price 136.87
1st Support Level 134.59
2nd Support Level 132.31
3rd Support Level 131.12

See More

52-Week High 168.11
Fibonacci 61.8% 153.97
Fibonacci 50% 149.61
Fibonacci 38.2% 145.24
Last Price 136.87
52-Week Low 131.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar